The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review.

[1]  N. Goel,et al.  Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. , 2022, The Journal of rheumatology.

[2]  K. Nouri,et al.  Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and 2015-2020: A Systematic Review. , 2022, JAMA dermatology.

[3]  A. Soliman,et al.  Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial , 2021, Annals of the Rheumatic Diseases.

[4]  L. Coates,et al.  Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) , 2021, Annals of the Rheumatic Diseases.

[5]  A. Soliman,et al.  Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial , 2021, Annals of the Rheumatic Diseases.

[6]  A. Mangoni,et al.  Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis. , 2021, Rheumatology.

[7]  A. Ogdie,et al.  The epidemiology of psoriatic arthritis: A literature review. , 2021, Best practice & research. Clinical rheumatology.

[8]  M. Magrey,et al.  Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. , 2021, The New England journal of medicine.

[9]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, Systematic Reviews.

[10]  W. Tillett,et al.  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 , 2020, Annals of the Rheumatic Diseases.

[11]  P. Mease,et al.  Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials , 2020, Annals of the Rheumatic Diseases.

[12]  A. Ogdie,et al.  Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry , 2020, The Journal of Rheumatology.

[13]  P. Helliwell,et al.  A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. , 2020, Rheumatology.

[14]  A. Gottlieb,et al.  Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[15]  A. Deodhar,et al.  Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[16]  J. Yazdany,et al.  Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials , 2019, JAMA network open.

[17]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[18]  H. Mann,et al.  Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study , 2019, Rheumatology and Therapy.

[19]  C. Edwards,et al.  Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial , 2018, Rheumatology.

[20]  D. M. van der Heijde,et al.  Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study , 2018, Annals of the rheumatic diseases.

[21]  J. Simard,et al.  The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus , 2018, Current Rheumatology Reports.

[22]  P. Rahman,et al.  Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) , 2018, Arthritis Research & Therapy.

[23]  J. Walsh,et al.  Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) , 2018, Annals of the rheumatic diseases.

[24]  A. Kavanaugh,et al.  Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis , 2017, Arthritis & rheumatology.

[25]  D. Gladman,et al.  Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors , 2017, The New England journal of medicine.

[26]  D. M. van der Heijde,et al.  Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis , 2017, The New England journal of medicine.

[27]  U. Wagner,et al.  Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial , 2017, The Lancet.

[28]  A. Gottlieb,et al.  Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis , 2017, Annals of the rheumatic diseases.

[29]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[30]  D. Gladman,et al.  Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 , 2016, Annals of the rheumatic diseases.

[31]  Yi-Hui Lee,et al.  A Review of Barriers to Minorities’ Participation in Cancer Clinical Trials: Implications for Future Cancer Research , 2016, Journal of Immigrant and Minority Health.

[32]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[33]  G. Kerr,et al.  Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden , 2015, Clinical Rheumatology.

[34]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[35]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[36]  J. Ortonne,et al.  Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.

[37]  Moon S. Chen,et al.  Twenty years post‐NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual , 2014, Cancer.

[38]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[39]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[40]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[41]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[42]  J. Fisher,et al.  Challenging assumptions about minority participation in US clinical research. , 2011, American journal of public health.

[43]  Vinod Chandran,et al.  Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. , 2010, Journal of autoimmunity.

[44]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[45]  J. Darmawan,et al.  Rheumatic Diseases in China , 2008, Arthritis research & therapy.

[46]  M. Genovese,et al.  Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. , 2007, Journal of Rheumatology.

[47]  R. Stern,et al.  Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.

[48]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[49]  A. Kavanaugh,et al.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial , 2005, Annals of the rheumatic diseases.

[50]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.